AbbVie ABBV
Valuation
Multiples measured against the stock's own five-year history
Above its usual level · 77th percentile, 5-year average 60.1x
#2739 of 2972 stocks by PE (1 = cheapest)
Near the bottom of its 5-year range · 15th percentile, 5-year average -96.7x
Near the top of its 5-year range · 100th percentile, 5-year average 5.5x
#4313 of 5150 stocks by PS (1 = cheapest)
P/E over five years
Dashed line is the 5-year average; the shaded band is one standard deviation either side.
Morningstar fair value estimate
| Multiple | Current | Forward | 5y average | Percentile vs. own history | Industry rank |
|---|---|---|---|---|---|
| PB | -87.79 | – | -96.66 | 15% (cheaper than usual) | – |
| PE | 83.30 | 28.60 | 60.05 | 77% (pricier than usual) | #2739 of 2972 (1 = cheapest) |
| PS | 7.89 | 7.31 | 5.47 | 100% (pricier than usual) | #4313 of 5150 (1 = cheapest) |
Percentile is against this stock’s own 5-year valuation range: higher means it’s trading rich relative to its own history, lower means cheap relative to its own history — it is not a comparison against other companies. Forward multiples use consensus estimates for the next twelve months; a forward multiple below the current one usually signals analysts expect earnings to grow.
No comments yet — be the first to weigh in on ABBV.
Sign in to join the discussion.